35P - Clinical significance of expression of cripto-1 in patients of squamous cell carcinoma of oropharynx

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Head and Neck Cancers
Translational Research
Presenter MALLUPATTU Kumar
Citation Annals of Oncology (2016) 27 (suppl_9): ix9-ix18. 10.1093/annonc/mdw574
Authors M.S. Kumar1, A. Pal2, A. Jain2, S. Ghoshal1, B. Rai1, S. Mohindra3, A. Das4
  • 1Radiotherapy, Post Graduate Institute of Medical Education and Research (PGIMER), 160012 - Chandigarh/IN
  • 2Biochemistry, Post Graduate Institute of Medical Education and Research (PGIMER), 160012 - Chandigarh/IN
  • 3Ent, Post Graduate Institute of Medical Education and Research (PGIMER), 160012 - Chandigarh/IN
  • 4Pathology, Post Graduate Institute of Medical Education and Research (PGIMER), 160012 - Chandigarh/IN

Abstract

Background

Most cancers of head and neck region present in an advanced stage. Early diagnosis of the disease may improve therapeutic outcome by increasing cure rates and decreasing morbidities. A biomarker can detect these tumors at an early stage. Cripto-1(CR-1), a teratoma derived growth factor, is overexpressed in certain tumors and found in the plasma of patients. This study was planned to study the over expression and clinical significance of CR-1 in patients with oropharyngeal squamous cell carcinoma(OSCC). The aim of the study is to correlate serum CR-1 levels in patients of OSCC with clinico-pathological features and response to treatment by a) comparing CR-1 levels between patients and controls b) correlating CR-1 levels with histological grade and stage of disease and c) comparing pre and post treatment CR-1 levels and correlate with disease status.

Methods

Fifty healthy volunteers(controls) and fifty biopsy proven cases of OSCC were recruited in the study after using inclusion and exclusion criteria. All patients were treated with radical chemo-radiation and response was assessed at 6 weeks post therapy. Serum CR-1 levels were analyzed by ELISA in patients, both before and after treatment, and also in controls. Expression of CR-1 was compared between controls and patients. Pre and post treatment CR-1 levels in patients were compared and correlated with clinic-pathological findings. SPSSv16.0 was used for statistical analysis.

Results

As compared to controls, serum CR-1 levels are significantly raised in patients with OSCC (207 pg/ml Vs 497 pg/ml, p=.003). CR-1 levels are significantly higher in patients with well differentiated and early stage tumors as compared to controls. CR-1 levels decreased significantly after treatment and correspond with response to therapy (497 pg/ml Vs 228 pg/ml, p=.046).

Conclusions

Human serum CR-1 is a potential tumor marker for OSCC. This study also suggests that CR-1 may be useful in early diagnosis of OSCC and merits larger, prospective studies

Clinical trial indentification

Legal entity responsible for the study

PGIMER, Chandigarh

Funding

PGIMER, Chandigarh, India

Disclosure

All authors have declared no conflicts of interest.